Adherence to preexposure prophylaxis: Current, emerging, and anticipated bases of evidence

Clinical Infectious Diseases

Volumn 59, Issue SUPPL.1, 2014, Pages

  Amico, K Rivet ^a,b   Stirratt, Michael J ^c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b Applied Health Research   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

behavioral science; PrEP adherence; social science; study product adherence

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PLACEBO;

ARTICLE; COGNITIVE THERAPY; DRUG DETERMINATION; HEALTH PROMOTION; HIV EDUCATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; MEDICATION COMPLIANCE; MOTIVATIONAL INTERVIEWING; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PRACTICE GUIDELINE; PREEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SEXUAL EDUCATION; SEXUAL HEALTH; SOCIAL ACCEPTANCE; UNITED STATES; FEMALE; HIV INFECTIONS; MALE; STATISTICS AND NUMERICAL DATA;

ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE;

EID: 84904816119     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu266     Document Type: Article

References (49)

1. Amico KR. Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness. Curr Opin HIV AIDS 2012; 7:542-8.
2. Baeten J, Celum C. Oral antiretroviral chemoprophylaxis: current status. Curr Opin HIV AIDS 2012; 7:514-9.
3. Celum CL. HIV preexposure prophylaxis: new data and potential use. Top Antivir Med 2011; 19:181-5.
4. Baeten JM, Grant R. Use of antiretrovirals forHIV prevention: what dowe know and what don't we know? Curr HIV/AIDS Rep 2013; 10:142-51.
5. Mayer K, Gazzard B, Zuniga JM, et al. Controlling the HIV epidemic with antiretrovirals: IAPAC consensus statement on treatment as prevention and preexposure prophylaxis. J Int Assoc Provid AIDS Care 2013; 12:208-16.
6. Karim QA, Baxter C, Karim SA. Topical microbicides-what's new? J Acquir Immune Defic Syndr 2013; 63(Suppl 2):S144-9.
7. Woodsong C, Macqueen K, Amico KR, et al. Microbicide clinical trial adherence: insights for introduction. J Int AIDS Soc 2013; 16:18505.
8. Amico K. Adherence to HIV treatment as prevention and preexposure prophylaxis. In: Eaton LA, Kalichman SC, eds. Biomedical advances in HIV prevention: social and behavioral perspectives. New York: Springer, 2014:69-108.
9. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-74.
10. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
11. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet 2013; 381:2083-90.
12. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99.
13. Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). In: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 2013.
14. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-34.
15. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411-22.
16. Hendrix CW. Exploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design. Cell 2013; 155: 515-8.
17. Eakle R, Venter WD, Rees H. Pre-exposure prophylaxis for HIV prevention: ready for prime time in South Africa? S Afr Med J 2013; 103:515-6.
18. Anderson PL, Lama J, Buchbinder S, et al. Interpreting detection rates of intracellular emtricitabine-triphosphate (FTC-TP) and tenofovir-diphosphate (TFV-DP) in the iPrEx trial. In: 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2011.
19. Haberer JE, Baeten JM, Campbell J, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med 2013; 10:e1001511.
20. Hosek SG, Siberry G, Bell M, et al. The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men. J Acquir Immune Defic Syndr 2013; 62:447-56.
21. Ambia JAK. Barriers and facilitators of adherence in user-dependent HIV prevention trials: a systematic review. Int STD Res Rev 2013; 1:12-29.
22. Ware NC, Wyatt MA, Haberer JE, et al. What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr 2012; 59:463-8.
23. Simon AE, Wu AW, Lavori PW, Sugarman J. Preventive misconception: its nature, presence, and ethical implications for research. Am J Prev Med 2007; 32:370-4. (Pubitemid 46660442)
24. Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS 2011; 25:279-90.
25. Minnis AM, Gandham S, Richardson BA, et al. Adherence and acceptability inMTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav 2013; 17:737-47.
26. Baeten JP, Palanee T. A multi-center, randomized, double-blind, placebo-controlled phase 3 safety and effectiveness trial of a vaginal matrix ring containing dapivirine for the prevention of HIV-1 infection in women. Available at: http://www.mtnstopshiv.org/sites/default/files/attachments/MTN- 020%20Version1%200-28September2011-CLEAN. pdf. Accessed January 2014.
27. Abraham BK, Gulick R. Next-generation oral preexposure prophylaxis: beyond tenofovir. Curr Opin HIV AIDS 2012; 7:600-6.
28. Spreen WR, Margolis DA, Pottage JC Jr. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIVAIDS 2013; 8:565-71.
29. Friend DR, Clark JT, Kiser PF, Clark MR. Multipurpose prevention technologies: products in development. Antiviral Res 2013; 100 (suppl):S39-47.
30. Saethre E, Stadler J. Malicious whites, greedy women, and virtuous volunteers: negotiating social relations through clinical trial narratives in South Africa. Med Anthropol Q 2013; 27:103-20.
31. Young I, McDaid L. How acceptable are antiretrovirals for the prevention of sexually transmitted HIV? A review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention. AIDS Behav 2014; 18:195-216.
32. Amico KR, Mansoor LE, Corneli A, Torjesen K, van der Straten A. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav 2013; 17:2143-55.
33. Altice FL, Friedland GH. The era of adherence to HIV therapy. Ann Intern Med 1998; 129:503-5. (Pubitemid 28428088)
34. Fisher JD, Fisher WA, Amico KR, Harman JJ. An information-motivation- behavioral skills model of adherence to antiretroviral therapy. Health Psychol 2006; 25:462-73. (Pubitemid 44167248)
35. Amico KR, McMahan V, Goicochea P, et al. Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment. AIDS Behav 2012; 16: 1243-59.
36. Magazi B. Influences on visit attendance in the VOICE trial: insights from a qualitative sub-study in Johannesburg, South Africa. In: 3rd Structural Drivers Conference, Cape Town, South Africa, 2013. Available at: http://www.heard.org.za/downloads/structural-drivers-2013/influences-on-visit- attendance-in-the-voice-trial-insights-from-aqualitative-sub-study-in- johannesburg-south-africa.pdf. Accessed 1 May 2014.
37. Grant R, McMahan V, Amico R, et al. Drug detection during open-label extension of the iPrEx trial indicates sustained and appropriate interest in PrEP among men who have sex with men. In: 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, Malaysia, 2013.
38. Mera RM, Rawlings MK, Pechonkina A, et al. Status of Truvada (TVD) for HIV preexposure prophylaxis (PrEP) in the United States: an early drug utilization analysis [poster H-663a]. In: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 2013.
39. Rollnick SM, Miller WR, Butler CC. Motivational interviewing in health care: helping patients change behavior (applications of motivational interviewing). Guilford Press, New York, 2008.
40. Safren SA, O'Cleirigh C, Tan JY, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol 2009; 28:1-10.
41. Safren SA, Otto MW, Worth JL, et al. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Behav Res Ther 2001; 39:1151-62. (Pubitemid 32743136)
42. Centers for Disease Control and Prevention. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 2011; 60:65-8.
43. Centers for Disease Control and Prevention. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep 2012; 61:586-9.
44. Centers for Disease Control and Prevention. Update to interim guidance for preexposure prophylaxis (PrEP) for the prevention of HIV infection: PrEP for injecting drug users. MMWR Morb Mortal Wkly Rep 2013; 62:463-5.
45. World Health Organization. Programmatic update: antiretroviral treatment as prevention (TasP) of HIV and TB. Geneva, Switzerland, 2012.
46. Amico KR, McMahan V, Marcus J, et al. Integrated next step counseling (iNSC): a discussion based sexual health promotion conversation to support men who have sex with men using PrEP in the iPrEx open label extension. In: 7th International Conference on HIV Treatment and Prevention Adherence, Miami, FL, 2012.
47. Wheeler DP, Fields SD. HPTN 073: pre-exposure prophylaxis (PrEP) initiation and adherence among black men who have sex with men (BMSM) in three US cities. Available at: http://www.hptn.org/web% 20documents/HPTN073/073V2- 2Jan2014.pdf. Accessed 1 May 2014.
48. Grant RM, van Griensven F. HPTN 067: the ADAPT study: a phase II, randomized, open-label, pharmacokinetic and behavioral study of the use of intermittent oral emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis (PrEP). Available at: http://www.hptn.org/web%20documents/HPTN067/ Protocol/067ProtocolV5-10Jun2013. pdf. Accessed 1 January 2014.
49. McCormack S. Pre-exposure options for reducing HIV in the UK: an open-label randomisation to immediate or deferred daily Truvada for HIV negative gay men (the PROUD Study). Available at: http://www. ctu.mrc.ac.uk/plugins/ StudyDisplay/protocols/PROUD-protocolv1-2-1-14Oct.pdf. Accessed 1 May 2014.